Publisher
Springer Science and Business Media LLC
Reference105 articles.
1. James, N. D. et al. The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet 403, 1683–1722 (2024).
2. Hague, C. & Logue, J. P. Clinical experience with radium-223 in the treatment of patients with advanced castrate-resistant prostate cancer and symptomatic bone metastases. Ther. Adv. Urol. 8, 175–180 (2016).
3. McBean, R., O’Kane, B., Parsons, R. & Wong, D. Lu277-PSMA therapy for men with advanced prostate cancer: initial 18 months experience at a single Australian tertiary institution. J. Med. Imaging Radiat. Oncol. 63, 538–545 (2019).
4. Fong, L. et al. A phase 1b study of atezolizumab with radium-223 dichloride in men with metastatic castration-resistant prostate cancer. Clin. Cancer Res. 27, 4746–4756 (2021).
5. Wang, S., Tang, W., Luo, H., Jin, F. & Wang, Y. The role of image-guided radiotherapy in prostate cancer: a systematic review and meta-analysis. Clin. Transl. Radiat. Oncol. 38, 81–89 (2023).